





**LXV INTERNATIONAL SCIENTIFIC  
CONFERENCE OF YOUNG SCIENTISTS  
"SCIENCE: YESTERDAY, TODAY, TOMORROW"**



**April 9 2026**



 sno\_zkmu  
 sno\_zkgmu



## INFORMATION LETTER

Dear Young Scientists!  
**MARAT OSPANOV WEST KAZAKHSTAN MEDICAL UNIVERSITY**  
invites you to participate in the

**LXV INTERNATIONAL SCIENTIFIC CONFERENCE OF YOUNG SCIENTISTS “SCIENCE: YESTERDAY, TODAY, TOMORROW,”**  
dedicated to the 80th anniversary of the Professor of Medicine,  
"Honorary Professor of the University" Marat Kapenovich Iztleuov,  
which will take place on April 9-10, 2026 year.



### Dear friends!

In 2026, our conference marks a special milestone — the 65th Anniversary Conference.

This date represents far more than a number; it embodies a rich history shaped by the dedication, aspirations, and inspiration of several generations of scientists and educators. The conference has always been a significant event in the scientific life of the university.

The jubilee significance of the conference is further underscored by the fact that it is being held in the year marking the 80th anniversary of the outstanding scientist, educator, and mentor—Doctor of Medical Sciences, "Honorary Professor of the University" Iztleuov Marat Kapenovich—whose contributions to the advancement of medical science and education have been profound.

Aktobe is a modern city with a well-developed infrastructure, a vibrant cultural environment, and a dynamic scientific community. It serves as a center of professional growth and inspiration for physician-scientists and educators who have made a substantial contribution to the advancement of medicine and science in our country.

West Kazakhstan Marat Ospanov Medical University is pleased to invite you to the 65th Anniversary Conference, where participants will have the opportunity to present their research findings, exchange professional experience, and discuss current scientific challenges



## The conference will be conducted across the following thematic sections:

- Morphology;
- Physiology;
- Experimental medicine and biomedicine;
- Actual problems of Infectology, dermatovenerology;;
- Ecology;
- Hygiene;
- Public Health;
- Internal Diseases and Related Disciplines;
- Surgical Diseases and Related Disciplines;
- Obstetrics and Gynecology, Reproductology;
- Oncology, Radiology, radiation medicine and nuclear medicine;;
- Pediatrics;
- Dentistry;
- Pathomorphology and Pathophysiology;
- Pathoanatomy and Forensic Medicine;
- Section for School and College Students;
- Poster Presentations;
- Philology and Intercultural Communication;
- Young Scientists in Theoretical Science;
- Young Scientists in Clinical Medicine;
- Digital medicine and artificial intelligence;

### Participation Format:

**Oral Presentation:** Up to 5 minutes for the presentation and 2 minutes for discussion. Slides must be prepared in Microsoft PowerPoint in accordance with the approved template (see Appendix 2).

**Poster Presentation:** abstracts must be submitted to the conference proceedings in full compliance with the established requirements. The poster should be designed in an 80 × 180 cm X-banner format, prepared in one of the working languages of the conference. The poster header must correspond to the abstract formatting used in the proceedings and should include illustrative materials. A sample design is provided in Appendix 3.

**Conference Venue:** West Kazakhstan Marat Ospanov Medical University, 66 Maresyev Street, Aktobe, Republic of Kazakhstan.

**Conference Hours:** 9:00 AM – 6:00 PM.



**The results of your research may be published in the form of an abstract.**

**Requirements for formatting abstracts:** Abstracts should be submitted in Kazakh, Russian, or English, with proper stylistic and orthographic formatting. The text should be typed in MS Word, font – Times New Roman (size 12), single-spaced; margins – 2 cm on all sides of the page, abstract volume – no more than 2 pages (A4 format), orientation – portrait, hyphenation-automatic, text alignment – width. According to Appendix 1.

**The title should be formatted as follows:** the first line (centered) - author(s) surname(s), initials in lowercase; second line (centered) - title of the work in uppercase bold font; third line-full name of the department; fourth line-academic advisor's full name (position, academic degree); fifth line (centered)-full name of the institution, city, and country; then – text of the abstract, aligned to justify.

Photos, illustrations, tables, and charts are not allowed. Abstracts that do not meet the requirements will be returned for correction. The file should be named after the first author's surname. If one author submits multiple works, the files should be named as "Surname First Initial 1," "Surname First Initial 2," for example: AlievaBL1, AlievaBL2.

**Abstracts should be signed by the scientific supervisor (scanned version).**

An abstract should contain:

- Relevance
- Purpose of research
- Research methods
- Results
- Conclusions
- List of References

\*Section titles should be highlighted in bold. Appendix 1.

**Abstracts are accepted in Kazakh, Russian, and English. The author(s) must submit a work that has not been published in other publications.**

**NB! Abstracts are accepted until February 28, 2026.**

**Submissions should be made electronically via the link:**

<https://forms.gle/LNgZ9kVB3ibCZRfs9>



2 CM

Ivanov I.I., Ivanova I.I.

## «HOPE» Study

Department of Internal Diseases №2

Research Supervisor: Doctor of Medical Science, professor Alimzhanov R.S.

Marat Ospanov West Kazakhstan Medical University

Aktobe city, Republic of Kazakhstan

**Relevance:** Coronary heart disease is becoming an epidemic. The World Health Organization (WHO) reports that 2/3 of deaths from cardiovascular diseases among people aged 45 to 64 years account for ischemic heart disease and mainly myocardial infarction (MI), associated with atherosclerosis of coronary arteries and especially increasing the risk of MI, comorbid disease - diabetes mellitus (DM). Lack of proper treatment, constant stress have an impact. The number of patients with cardiac problems is steadily increasing, which affects the country's economy. The HOPE study was based on the idea that ACE inhibitors have antiatherosclerotic properties, which contributed to a reduction in the incidence of myocardial infarction when treated with enalapril compared to placebo in patients with left ventricular dysfunction.

**Purpose of the study:** Evaluation of the therapeutic effects of tissue ACE inhibition, as well as the effect of ramipril on individual endpoint components, i.e., risk of myocardial infarction, stroke, and cardiovascular death, as well as overall mortality, development of heart failure, need for revascularization, and incidence of diabetic complications.

**Research methods:** The study included 9451 high-risk patients (mean age of 55 years). They had signs of vascular disease or diabetes mellitus and at least 1 additional risk factor, but no heart failure or reduced left ventricular ejection fraction. Patients were treated with the ACE inhibitor ramipril or placebo. The duration of therapy averaged 4.5 years, and the primary endpoint of the study was the cumulative incidence of MI, stroke, and death from cardiovascular disease.

**Results:** The study demonstrated a reduction in the cumulative risk of cardiovascular complications. Treatment with ramipril also reduced cardiovascular mortality, risk of myocardial infarction and risk of stroke. The study showed a reduced risk of heart failure, revascularization necessity and macro- and microvascular complications of diabetes mellitus.

**Conclusions:** Ramipril significantly reduced the risk of death, myocardial infarction and stroke in a wide range of high-risk patients who did not have reduced ejection fraction or heart failure. Another important but negative outcome of the study was the ineffectiveness of vitamin E, although previous studies have demonstrated the benefit of vitamins. This is important because many people take vitamins despite the lack of evidence of their beneficial effects.

2 CM



Name of Educational Institution

Name of Department



# TOPIC OF SCIENTIFIC WORK

Full name of Authors

Course and Faculty

Research Supervisor:

Academic degree, position and full name

Slides MUST contain following sections:

- 
1. Relevance
  2. Purpose of research
  3. Research methods
  4. Results
  5. Conclusions

Presentation if applicable should contain illustrations (photos, diagrams, tables etc.)


64-я НАУЧНАЯ КОНФЕРЕНЦИЯ СТУДЕНТОВ И МОЛОДЫХ УЧЕНЫХ ЗАПАДНО-КАЗАХАСТАНСКОГО МЕДИЦИНСКОГО УНИВЕРСИТЕТА ИМЕНИ МАРАТА ОСПАНОВА  
Иванов И.И., Петров П.П.

## ИССЛЕДОВАНИЕ «НОРЕ»

Кафедра внутренних болезней №2 Научный руководитель – д.м.н., профессор  
Алимжанова Р.С.  
Западно-Казакстанский государственный медицинский университет имени Марата  
Оспанова  
город Актобе, Республика Казахстан




180см




С каждым годом ишемическая болезнь сердца приобретает эпидемиологический характер. ВОЗ сообщает, что 2/3 смертельных исходов от сердечно – сосудистых болезней среди лиц в возрасте от 45 до 64 лет приходится на долю ишемической болезни сердца и главным образом инфаркта миокарда.


В исследование «НОРЕ» было включено 9451 больной группы высокого риск (средний возраст 55 лет). У них имелись признаки сосудистых заболеваний или сахарный диабет, а также, по крайней мере, 1 дополнительный фактор риска, но отсутствовали сердечная недостаточность или снижение фракции выброса левого желудочка. Пациентам назначали ингибитор АПФ **рамиприл** или **плацебо**. Длительность терапии составила в среднем 4,5 года, а первичной конечной точкой исследования была суммарная частота ИМ, инсульта и смерти от сердечно – сосудистых заболеваний.



Комбинированная конечная точка в исследовании NOPE (сердечно-сосудистая смерть, инфаркт, инсульт)



Комбинированная конечная точка в исследовании NOPE



Развитие сердечной недостаточности в исследовании NOPE

Исследование «НОРЕ» продемонстрировало снижение суммарного риска сердечно – сосудистых осложнений. Лечение рамиприлом привело также к снижению сердечно – сосудистой смертности, риска инфаркта миокарда и риска инсульта. В исследовании выявлено снижение риска развития сердечной недостаточности, реваскуляризации и макро – и микрососудистых осложнений сахарного диабета.

80см



**NB!!! 1. Abstracts that do not comply with all stated requirements will not be accepted. 2. Submission of materials that have been previously published or are under consideration for publication in other journals or by other publishers is not permitted. 3. The Organizing Committee reserves the right to review submissions, assign papers to conference sections, and make editorial corrections (spelling and punctuation). 4. The Organizing Committee is not responsible for the content of submitted articles. 5. All submitted posters must be reviewed and approved by the Organizing Committee prior to the conference. 6. Only oral and poster presentations will be included in the conference program. 7. In the event of a large number of submissions, the Organizing Committee reserves the right to select oral presentations. 8. When submitting an abstract, authors must provide contact telephone numbers for both the presenting author and the scientific supervisor. 9. If there is an insufficient number of papers in a particular section, the Organizing Committee reserves the right to reassign papers to related sections. 10. The collection of abstracts will be publicly available on the website of Marat Ospanov West Kazakhstan Medical University (ZKMU) in the “Conference Series” section: <https://zkmu.edu.kz/ru/maratospanov-atyndary-bkmu-konferenciya-seriyasy/> 11. Authors bear full responsibility for the unauthorized use of intellectual property and copyright violations in their scientific articles in accordance with the legislation of the Republic of Kazakhstan.**

**Organizational Fee:** 5000 tenge. Payment should be made to the account listed below, a copy of the payment receipt must be provided to the organizing committee. For non-local participants attending in person, payment can be made during registration on the day of the conference.

**Payment Account: KZ1794803KZT22031354**  
**ОО "ЕВРАЗИЙСКАЯ ОРГАНИЗАЦИЯ МОРФОЛОГОВ"**  
**Bank BIN 190840029965**

**Beneficiary: Resident of Republic of Kazakhstan**  
**Beneficiary code: 17**  
**Payment code: 171**

**Purpose of payment: "Membership fee for the conference."**





## Organizing Committee

1. Amirbekova Alfiya Armanbekovna - Secretary of the SSS NAO “Marat Ospanov West Kazakhstan Medical University” +7 771 977 64 12;
2. Alibekov Kadyrbek Asylbekovich - responsible for accepting abstracts of the SSS NAO “Marat Ospanov West Kazakhstan Medical University” +7 777 747 55 02;
3. Bekniyazova Aisulu Nurbolovna - responsible for accepting abstracts of the SSS NAO “Marat Ospanov West Kazakhstan Medical University” +7 705 818 68 57;
4. Tulegenova Dana Alisherovna - responsible for the sections of the conference of the SSS NAO “Marat Ospanov West Kazakhstan Medical University” +7 702 130 27 29;
5. Darina Sergeevna Vedyushkina - Responsible for the sections of the conference of the SSS NAO Student Scientific Society Conference Sections “Marat Ospanov West Kazakhstan Medical University” +7 702 258 41 76;
6. AlikoTalgatovna Makhatova - Responsible for the sections of the conference of the SSS NAO Student Scientific Society Conference Sections “Marat Ospanov West Kazakhstan Medical University” +7 778 940 05 59;

**See you at the conference!**

